Dual-targeted anti-TB/anti-HIV heterodimers

Antiviral Res. 2017 Sep:145:175-183. doi: 10.1016/j.antiviral.2017.07.011. Epub 2017 Jul 22.

Abstract

HIV and M. tuberculosis are two intersecting epidemics making the search for new dual action drugs against both pathogens extremely important. Here, we report on the synthesis and suppressive activities of five dual-targeted HIV/TB compounds. These compounds are heterodimers of AZT, as anti-HIV molecules, and 5-substituted uracil derivatives, as anti-TB molecules. We found that these compounds inhibit the growth of M. tuberculosis and suppress the replication of HIV in human cell cultures and human lymphoid tissues ex vivo. We identified one particular heterodimer that inhibited both HIV and the drug-resistant TB strain MS-115 most potently. This compound demonstrated low toxicity and had no cytostatic effect on cells in culture, constituting an ideal candidate for future development and further in vivo testing.

Keywords: HIV; Heterodimers; Human tissues; TB.

MeSH terms

  • Antitubercular Agents / chemistry*
  • Antitubercular Agents / pharmacology
  • Antitubercular Agents / therapeutic use
  • Cell Culture Techniques
  • Cells, Cultured
  • Drug Design*
  • Drug Resistance, Multiple, Bacterial
  • HIV Infections / drug therapy*
  • HIV-1 / drug effects
  • Humans
  • Lymphocytes / drug effects
  • Lymphocytes / microbiology
  • Lymphocytes / virology
  • Mycobacterium tuberculosis / drug effects
  • Mycobacterium tuberculosis / growth & development
  • Tuberculosis / drug therapy*
  • Virus Replication / drug effects
  • Zidovudine / chemistry*
  • Zidovudine / pharmacology
  • Zidovudine / therapeutic use

Substances

  • Antitubercular Agents
  • Zidovudine